StockNews.com began coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a research report report published on Thursday. The firm issued a sell rating on the biopharmaceutical company's stock.
A number of other equities research analysts also recently weighed in on the stock. Leerink Partnrs downgraded shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners reiterated a "market perform" rating and set a $1.00 target price (down from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. Piper Sandler decreased their price target on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Lexicon Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $3.67.
Check Out Our Latest Research Report on LXRX
Lexicon Pharmaceuticals Stock Performance
NASDAQ LXRX traded up $0.02 on Thursday, reaching $0.36. The stock had a trading volume of 4,216,595 shares, compared to its average volume of 4,005,267. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The company has a market cap of $89.43 million, a P/E ratio of -0.48 and a beta of 1.04. The firm has a fifty day moving average of $0.64 and a two-hundred day moving average of $1.04. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.47.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The business had revenue of $26.55 million for the quarter, compared to the consensus estimate of $6.48 million. On average, equities research analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.
Institutional Trading of Lexicon Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of LXRX. FMR LLC raised its stake in Lexicon Pharmaceuticals by 28.9% during the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company's stock worth $78,291,000 after acquiring an additional 11,179,919 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Lexicon Pharmaceuticals by 630.7% during the 4th quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company's stock valued at $6,638,000 after purchasing an additional 7,758,371 shares during the last quarter. Schonfeld Strategic Advisors LLC increased its position in Lexicon Pharmaceuticals by 301.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company's stock worth $5,582,000 after purchasing an additional 5,676,021 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in Lexicon Pharmaceuticals by 186.6% in the 4th quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company's stock valued at $4,877,000 after purchasing an additional 4,300,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Lexicon Pharmaceuticals by 8.4% in the third quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company's stock valued at $5,534,000 after buying an additional 273,436 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Further Reading
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
